Target intelligence / Profile preview

Human mast cell β-tryptase (β-tryptase)

Target
β-tryptase
Molecular classification
Enzyme, Serine protease, Secretory granule protein
01

Overview

Human mast cell β-tryptase is a trypsin-like serine protease and the major secretory granule protease of human mast cells. Encoded by the TPSAB1 and TPSB2 genes on chromosome 16p13.3, β-tryptase forms a homotetrameric structure stabilized by heparin proteoglycans, with active sites oriented toward the inner cavity of the tetramer. It is released upon mast cell activation and is resistant to most endogenous protease inhibitors. β-Tryptase plays key roles in mediating allergic inflammation, airway hyperresponsiveness, tissue remodeling, and the pathogenesis of asthma and anaphylaxis. Levels are elevated in conditions such as anaphylactic shock and systemic mastocytosis, making it a useful biomarker. Therapeutically, inhibition of β-tryptase is being pursued to treat inflammatory and allergic diseases

Other names
Mast cell tryptaseTryptase beta-1Tryptase IMast cell protease IIMast cell serine proteinase IIMast cell neutral proteinase
02

Mechanism of action

Competitive inhibition of β-tryptase’s serine protease active site; Allosteric inhibition disrupting tetramer stabilization; Inhibition of PAR-2 activation; Blockade of mast cell degranulation and mediator release

03

Biological functions

Immune responseAllergic and inflammatory mediator releaseExtracellular matrix remodelingActivation of protease-activated receptor 2 (PAR-2)Proliferation of smooth muscle cells, fibroblasts, and epithelial cells
04

Disease associations

InflammationAllergyAnaphylaxisAsthma and airway hypersensitivitySystemic mastocytosisEosinophilic leukemias
05

Safety considerations

Off-target protease inhibition (risk of interfering with normal immune or tissue functions)Possible impairment of host defense and wound healingAllergic or hypersensitivity reactions to drug candidates targeting tryptase
06

Interacting drugs

Tryptase inhibitors (several synthetic small-molecule inhibitors in preclinical or clinical investigation; one example is leech-derived tryptase inhibitor, LDTI)
07

Biomarkers

Serum tryptase levels (diagnosis and monitoring of anaphylaxis, systemic mastocytosis, mast cell activation syndromes)

Beyond the preview

Go deeper on Human mast cell β-tryptase (β-tryptase).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human mast cell β-tryptase (β-tryptase).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call